肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 BSH指南：经典霍奇金淋巴瘤的一线治疗

2022-02-22 英国血液病学学会 Br J Haematol

霍奇金淋巴瘤淋巴瘤

2022年2月，英国血液病学学会(BSH)发布了经典霍奇金淋巴瘤的一线治疗指南。本文主要针对成人经典霍奇金淋巴瘤的临床管理提供指导建议，内容涉及治疗前评估，各期疾病的治疗，不同人群的治疗以及随访等。

中文标题：

2022 BSH指南：经典霍奇金淋巴瘤的一线治疗

英文标题：

Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline

发布机构：

英国血液病学学会

发布日期：

2022-02-22

简要介绍：

2022年2月，英国血液病学学会(BSH)发布了经典霍奇金淋巴瘤的一线治疗指南。本文主要针对成人经典霍奇金淋巴瘤的临床管理提供指导建议，内容涉及治疗前评估，各期疾病的治疗，不同人群的治疗以及随访等。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 BSH指南：经典霍奇金淋巴瘤的一线治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=76a401c0023632fe, title=2022 BSH指南：经典霍奇金淋巴瘤的一线治疗, enTitle=Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline, guiderFrom=Br J Haematol, authorId=0, author=, summary=2022年2月，英国血液病学学会(BSH)发布了经典霍奇金淋巴瘤的一线治疗指南。本文主要针对成人经典霍奇金淋巴瘤的临床管理提供指导建议，内容涉及治疗前评估，各期疾病的治疗，不同人群的治疗以及随访等。, cover=https://img.medsci.cn/2022223/1645625572289_1608702.jpg, journalId=0, articlesId=null, associationId=1339, associationName=英国血液病学学会, associationIntro=, copyright=0, guiderPublishedTime=Tue Feb 22 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年2月，英国血液病学学会(BSH)发布了经典霍奇金淋巴瘤的一线治疗指南。本文主要针对成人经典霍奇金淋巴瘤的临床管理提供指导建议，内容涉及治疗前评估，各期疾病的治疗，不同人群的治疗以及随访等。</span></p>, tagList=[TagDto(tagId=350, tagName=霍奇金淋巴瘤), TagDto(tagId=412, tagName=淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4472, appHits=160, showAppHits=0, pcHits=747, showPcHits=4312, likes=0, shares=51, comments=10, approvalStatus=1, publishedTime=Thu Feb 24 15:10:00 CST 2022, publishedTimeString=2022-02-22, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed Feb 23 22:16:30 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Wed Jan 03 23:19:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 BSH指南：经典霍奇金淋巴瘤的一线治疗.pdf)])
2022 BSH指南：经典霍奇金淋巴瘤的一线治疗.pdf
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2166525, encodeId=a0e9216652552, content=<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22eb8222241, createdName=ms6000000108225303, createdTime=Fri Nov 03 17:19:57 CST 2023, time=2023-11-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2100911, encodeId=678121009110b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da35408927, createdName=ms3000002057134316, createdTime=Wed Nov 16 17:05:59 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220204, encodeId=7044122020435, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Tue May 17 08:40:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213946, encodeId=d74e1213946d8, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50372872263, createdName=天天爱学习, createdTime=Sun Apr 24 18:28:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211015, encodeId=f19c12110158d, content=要是有全文就更好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44ee2199321, createdName=120ae86am56(暂无昵称), createdTime=Thu Apr 14 00:00:06 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
    2023-11-03 ms6000000108225303 来自福建省

    #淋巴瘤#学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2166525, encodeId=a0e9216652552, content=<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22eb8222241, createdName=ms6000000108225303, createdTime=Fri Nov 03 17:19:57 CST 2023, time=2023-11-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2100911, encodeId=678121009110b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da35408927, createdName=ms3000002057134316, createdTime=Wed Nov 16 17:05:59 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220204, encodeId=7044122020435, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Tue May 17 08:40:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213946, encodeId=d74e1213946d8, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50372872263, createdName=天天爱学习, createdTime=Sun Apr 24 18:28:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211015, encodeId=f19c12110158d, content=要是有全文就更好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44ee2199321, createdName=120ae86am56(暂无昵称), createdTime=Thu Apr 14 00:00:06 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
    2022-11-16 ms3000002057134316

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2166525, encodeId=a0e9216652552, content=<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22eb8222241, createdName=ms6000000108225303, createdTime=Fri Nov 03 17:19:57 CST 2023, time=2023-11-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2100911, encodeId=678121009110b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da35408927, createdName=ms3000002057134316, createdTime=Wed Nov 16 17:05:59 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220204, encodeId=7044122020435, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Tue May 17 08:40:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213946, encodeId=d74e1213946d8, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50372872263, createdName=天天爱学习, createdTime=Sun Apr 24 18:28:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211015, encodeId=f19c12110158d, content=要是有全文就更好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44ee2199321, createdName=120ae86am56(暂无昵称), createdTime=Thu Apr 14 00:00:06 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
    2022-05-17 ms3000000771933475

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2166525, encodeId=a0e9216652552, content=<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22eb8222241, createdName=ms6000000108225303, createdTime=Fri Nov 03 17:19:57 CST 2023, time=2023-11-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2100911, encodeId=678121009110b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da35408927, createdName=ms3000002057134316, createdTime=Wed Nov 16 17:05:59 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220204, encodeId=7044122020435, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Tue May 17 08:40:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213946, encodeId=d74e1213946d8, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50372872263, createdName=天天爱学习, createdTime=Sun Apr 24 18:28:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211015, encodeId=f19c12110158d, content=要是有全文就更好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44ee2199321, createdName=120ae86am56(暂无昵称), createdTime=Thu Apr 14 00:00:06 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
    2022-04-24 天天爱学习

    ***

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2166525, encodeId=a0e9216652552, content=<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22eb8222241, createdName=ms6000000108225303, createdTime=Fri Nov 03 17:19:57 CST 2023, time=2023-11-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2100911, encodeId=678121009110b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da35408927, createdName=ms3000002057134316, createdTime=Wed Nov 16 17:05:59 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220204, encodeId=7044122020435, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Tue May 17 08:40:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213946, encodeId=d74e1213946d8, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50372872263, createdName=天天爱学习, createdTime=Sun Apr 24 18:28:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211015, encodeId=f19c12110158d, content=要是有全文就更好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44ee2199321, createdName=120ae86am56(暂无昵称), createdTime=Thu Apr 14 00:00:06 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
    2022-04-14 120ae86am56(暂无昵称)

    要是有全文就更好了

    0

相关指南

墨西哥专家共识：霍奇金淋巴瘤

国外血液科相关专家小组 · 2021-07-28

JSH实践指南：血液恶性肿瘤—Ⅱ淋巴瘤：霍奇金淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-11-29

2018 ESMO临床实践指南：霍奇金淋巴瘤的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2018-05-23